T. Rowe Price Associates’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-26,000
| Closed | -$128K | – | 3099 |
|
|
2021
Q3 | $128K | Sell |
26,000
-7,700
| -23% | -$37.4K | ﹤0.01% | 2800 |
|
|
2021
Q2 | $178K | Sell |
33,700
-30,000
| -47% | -$155K | ﹤0.01% | 2756 |
|
|
2021
Q1 | $306K | Hold |
63,700
| – | – | ﹤0.01% | 2561 |
|
|
2020
Q4 | $276K | Hold |
63,700
| – | – | ﹤0.01% | 2451 |
|
|
2020
Q3 | $262K | Sell |
63,700
-20,600
| -24% | -$79.7K | ﹤0.01% | 2338 |
|
|
2020
Q2 | $216K | Sell |
84,300
-1,439
| -2% | -$4.23K | ﹤0.01% | 2340 |
|
|
2020
Q1 | $248K | Buy |
85,739
+16,800
| +24% | +$75.3K | ﹤0.01% | 2251 |
|
|
2019
Q4 | $261K | Buy |
68,939
+10,011
| +17% | +$47.9K | ﹤0.01% | 2355 |
|
|
2019
Q3 | $301K | Buy |
58,928
+131
| +0.2% | +$809 | ﹤0.01% | 2279 |
|
|
2019
Q2 | $365K | Buy |
58,797
+46,200
| +367% | +$266K | ﹤0.01% | 2242 |
|
|
2019
Q1 | $90K | Buy |
12,597
+100
| +0.8% | +$899 | ﹤0.01% | 2476 |
|
|
2018
Q4 | $107K | Sell |
12,497
-4,164
| -25% | -$54.2K | ﹤0.01% | 2484 |
|
|
2018
Q3 | $334K | Buy |
16,661
+129
| +0.8% | +$3.03K | ﹤0.01% | 2318 |
|
|
2018
Q2 | $427K | Buy |
+16,532
| New | +$458K | ﹤0.01% | 2210 |
|
T. Rowe Price Associates's ADMS Position: Q4 2021 in Review
T. Rowe Price Associates sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 26,000 shares — an estimated $128K sold.
T. Rowe Price Associates first reported a position in ADMS in Q2 2018 and held it in 14 quarters. The position peaked at $427K in Q2 2018. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- T. Rowe Price Associates reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- T. Rowe Price Associates sold 26,000 Adamas Pharmaceuticals shares in Q4 2021, an estimated $128K.
- T. Rowe Price Associates first reported a position in Adamas Pharmaceuticals in Q2 2018 and held it in 14 quarters.
- T. Rowe Price Associates's Adamas Pharmaceuticals position peaked at $427K in Q2 2018.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.